ESSA Pharma Inc (Nasdaq: EPIX), a clinical-stage pharmaceutical company that says it is focused on developing novel therapies for the treatment of prostate cancer, announced on Monday that it has completed an underwritten public offering of 4,830,918 of its common shares.
The shares are priced at USD27 per share before underwriting discounts. The company granted the underwriters a 30-day option to purchase up to an additional 724,637 common shares. The total proceeds from the offering were around USD130m. The joint book-running managers for the offering are Jefferies and Piper Sandler, while lead manager for the offering is Oppenheimer & Co and Bloom Burton Securities Inc acted as co-manager for the offering.
The company aims to use the net proceeds from the offering to fund clinical activities, chemistry, manufacturing and controls, and research and development, working capital and general corporate purposes.
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
Celltrion USA launches denosumab biosimilars STOBOCLO and OSENVELT (denosumab-bmwo) in US
HotSpot Therapeutics presents small molecule CBM signalosome inhibitor program data
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
Biocon Biologics' Denosumab biosimilars receive European Commission approval
Amgen's Phase 3 bemarituzumab plus chemotherapy clinical trial meets primary endpoint
TuHURA Biosciences acquires Kineta
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies